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Abstract
Introduction: The use of human recombinant activated protein C (rhAPC) for the treatment of severe sepsis
remains controversial despite multiple reported trials. The efficacy of rhAPC remains a matter of dispute. We
hypothesized that patients with septic shock who were treated with rhAPC had an improved in-hospital mortality
compared to patients with septic shock with similar acuity who did not receive rhAPC.
Methods: This retrospective cohort study was completed at a large university-affiliated hospital. All patients with
septic shock admitted to a 50-bed ICU between July 2003 and February 2009 were included. Patients were treated
according to sepsis management guidelines.
Results: A total of 563 septic shock patients were included (110 received rhAPC and 453 did not). Treated and
untreated groups were matched in patient characteristics, comorbidities, and physiologic variables in a 1:1
propensity-matched analysis (108 received rhAPC, 108 did not). Mean Acute Physiology And Chronic Health
Evaluation II (APACHE II) scores were 24.5 for the matched treated and 23.9 for the matched untreated group (P =
0.54). Receipt of rhAPC was associated with reduced in-hospital mortality (35.2% vs. 53.8%, P = 0.005), similar mean
days on vasopressors (2 vs. 2, P = 0.90), similar mean days on mechanical ventilation (9 vs. 8.7, P = 0.80), similar
mean length of ICU stay in days (11.0 vs. 11.3, P = 0.90), and similar mean length of hospital stay in days (19.5 vs
27, P = 0.11). No patients in either group had intracranial bleeding; differences in gastrointestinal bleeding and
transfusion requirements were not statistically significant.
Conclusions: Patients in our institution with septic shock who were treated with rhAPC had a reduced in-hospital
mortality compared with patients with septic shock with similar acuity who were not treated with rhAPC. In
addition, time on mechanical ventilation, time on vasopressors, lengths of stay and bleeding complications did not
differ between the groups.
Introduction
In the United States alone, approximately 750,000 cases
of sepsis occur each year, of which at least 225,000 are
fatal. One study evaluating the epidemiology of sepsis
between 1979 and 2000 showed an 8.7% increase in the
annual incidence of sepsis. The cost of management of a
septic patient is approximately $50,000 amounting to
annual costs estimated at $17 billion. Sepsis is the second
leading cause of death in noncoronary Intensive Care
Units (ICUs), and the 10
th leading cause of death overall.
Organ failure occurs in 33.6% of patients with sepsis.
Severe sepsis carries an estimated 30 to 50% mortality.
Seventy percent of patients with three or more organ
failures die. Those who survive severe sepsis have a lower
quality of life compared to the age- and gender-adjusted
general population, as much as 1.5 years later [1-7].
Sepsis is a complex syndrome that remains incomple-
tely understood. It has proven very difficult to tailor new
therapies for severe sepsis. One such potential therapy is
Recombinant Human Activated Protein C (rhAPC). The
use of rhAPC for the treatment of severe sepsis remains
controversial despite multiple reported trials [8-13]. The
Prospective Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) trial
reported a 6% absolute reduction in mortality together
with a 1.5% absolute increase in the risk of serious bleed-
ing in patients receiving rhAPC compared to those
receiving placebo [8]. In a subgroup analysis of the PRO-
WESS trial, patients with higher risk of death had a larger
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lower risk of death. In patients with Acute Physiologic
and Chronic Health Evaluation II (APACHE II) score
>25, hospital mortality dropped from 47.9% to 36.7% (P
= 0.002) with rhAPC treatment [9]. In patients with
three, four, or five organ failures, hospital mortality
dropped from 37.0% to 30.5%, 50.1% to 44.9%, and 63.3%
to 32.5%, respectively [9]. In contrast, a subsequent trial
suggested that patients with lower mortality risk did not
benefit [10]. Widespread clinical use of rhAPC has likely
also been limited by its cost estimated at $7,500 to
$9,000 per course of therapy [14-16].
Two large multicenter trials evaluating the effect of
rhAPC in septic shock patients are currently underway
[17,18]. We examined the association between rhAPC
and outcomes in septic shock patients in our institution,
with the hypothesis that patients with septic shock who
were treated with rhAPC had an improved in-hospital
mortality compared to patients with septic shock with
similar acuity who did not receive rhAPC.
Materials and methods
Subjects
This investigation is a retrospective cohort study of
patients admitted to a large university affiliated hospital
with 56 medical-surgical intensive care unit (ICU) beds,
between July 2003 and February 2009. Data were
obtained from a large, multiinstitutional, critical care
patient data set (Project Impact Critical Care Data Sys-
tem). Project IMPACT (PI) is a comprehensive database
system developed to measure and describe the care of
ICU patients. Developed by a multidisciplinary group of
critical care expert members of the Society of Critical
Care Medicine, this system allows practitioners to quan-
tify practice patterns and patient outcomes and compare
them with those of similar ICUs. Personnel at >100
ICUs at multiple participating hospitals enter informa-
tion for >100 defined patient data elements into the PI
software. Data elements include patient demographics,
treatment, outcomes, complications, and resource utili-
zation. On a quarterly basis, data from all hospitals are
merged into the PI central database. Reports are then
generated that include both summary and individual
hospital data. Specifically, data on age, height, ICU
admission weight, gender, comorbidities, organ failures,
and ICU and hospital LOS were collected. PI data at
our institution were collected by experienced registered
ICU nurses (more than 16 years experience). Additional
data elements were collected from the patients’ electro-
nic medical records.
Patients were included if they were 18 years of age or
older, had a principal diagnosis of sepsis as defined by
the 1992 SCCM/ACCP consensus conference definition
[19], admitted to the ICU, and if they developed systolic
blood pressure less than 90 mmHg, not responding to
appropriate fluid resuscitation, and requiring vasopres-
sors to maintain mean arterial pressure greater than or
equal to 65 mmHG [19]. All sepsis patients in our insti-
tution are managed based on current sepsis manage-
ment guidelines [20,21].
Baseline characteristics including demographic infor-
mation and information about preexisting conditions,
organ function/failure, infection, and pertinent medica-
tions were collected. APACHE II scores and sequential
organ failure assessment (SOFA) scores were calculated.
In all patients that received rhAPC, the infusion was
started within 24 hours of development of septic shock.
Presence or development of acute organ failures was
documented. Organ failure definitions are shown in
Table 1. The conduction of this study was approved by
the Institutional Review Board at St. John’s Mercy Medi-
cal Center (Approval #10-084). The board waived the
need for informed consent.
Outcomes
The primary outcome measure was in-hospital mortality.
We also recorded complications, including the occurrence
of intracranial hemorrhage, gastrointestinal hemorrhage,
major transfusions, and minor transfusions. Major transfu-
sion was defined as the administration of six or more units
of red blood cells within two consecutive days or four or
more units in any single day. Minor transfusion was
defined as the administration of two or three units of
packed red blood cells in a single day. ICU-specific out-
comes included length of stay, number of days spent on
vasopressors and number of days on mechanical ventila-
tion. We also assessed hospital length of stay.
Analysis
Summary statistics were calculated for categorical and
numeric data. For categorical data, frequencies and pro-
portions (as percentages) are reported. For numeric
data, means, standard deviations, medians and lower
and upper quartiles are reported. Propensity for treat-
ment with rhAPC was estimated by fitting a nonparsi-
monious logistic regression model containing 22
independent variables (Table 2). These variables were
selected because they conceivably could bear on the
choice to administer rhAPC. The c statistic was 0.75.
The Hosmer-Lemeshow chi-square was 12.55 (df = 8),
with a non-significant P-value of 0.13, which indicates
the model is well-calibrated. Once the propensity scores
were obtained, we used the recently described “fine
balance” method of Rosenbaum, Ross, and Silber to pro-
duce 1:1 matched subjects [22]. Out of an overall num-
ber of 563 cases, we obtained 108 individuals treated
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treated with rhAPC.
Table 2 shows the characteristics of the treated and
untreated matched subjects. No statistically significant
differences were found, indicating that the matching
process succeeded in identifying comparable pairs of
individuals. All statistical tests took into account the
paired nature of the data. There may be some differ-
ences between the overall cohort and the matched
groups, but propensity matching has proved to be the
best method for dealing with those differences. Table 3
shows the outcomes by treatment. All statistical tests
took pairing into account, except for comparisons of
lengths of stay and days on ventilator and vasopressors.
These four comparisons were limited to survivors,
which caused pairing to be broken.
Results
A total of 563 septic shock patients were included (110
received rhAPC and 453 did not). Treated and untreated
groups were matched in patient characteristics, comor-
bidities, physiologic variables, organ failures, and
APACHE II scores (Table 2). Mean APACHE II scores
were 24.5 for the matched treated and 23.9 for the
matched untreated group (P = 0.54). In a 1:1 propen-
sity-matched analysis, receipt of rhAPC was associated
with reduced in-hospital mortality (35.2% vs. 53.8%, P =
0.005), similar mean days on vasopressors (2 vs. 2, P =
0.90), similar mean days on mechanical ventilation (9 vs.
8.7, P = 0.80), similar mean length of ICU stay in days
(11.0 vs. 11.3, P = 0.9), and similar mean length of hos-
pital stay in days (19.5 vs 27, P = 0.11). No patients in
either group had intracranial bleeding. Differences in
major transfusions (3.7% vs 9.3%, P = 0.09), minor
transfusions (35.2% vs 41.7%, P = 0.27), any transfusion
(minor and/or major, 38% vs 46.3%, P = 0.16) and gas-
trointestinal bleeding (2.8% vs 0%, P =1 . 0 0 )w e r en o t
statistically significant (Table 3).
Discussion
In this cohort propensity-matched analysis study, we
found that patients with septic shock who were treated
with rhAPC had a reduced in-hospital mortality com-
pared with patients with septic shock with similar acuity
who were not treated with rhAPC, with a relative risk
reduction of 34.6%, and absolute risk reduction of
18.6%. This translates into a number needed to treat
(NNT) to prevent a death of 5.4. We also found that the
rate of bleeding in our cohort was similar to other pub-
lished studies. In the major clinical trials, over the
28-day study period, serious bleeding events were
observed in 3.5 to 6.5% of patients receiving rhAPC as
compared with 2.0 to 5.0% of patients receiving the pla-
cebo [23]. Rates of intracranial hemorrhage were 0 to
1.5% with rhAPC as compared with 0 to 0.7% with the
placebo.
The first large randomized trial studied a dose of
24 μg per kilogram of body weight per hour in the
phase 3 PROWESS study [8]. This placebo-controlled,
randomized, double-blind, multicenter trial included
1,690 patients. Treatment with rhAPC within 24 hours
after diagnosis was associated with a mortality rate of
24.7% at 28 days versus 30.8% with placebo (P =0 . 0 0 5 ) .
The overall incidence of at least one bleeding event was
24.9% in the treatment group and 17.7% in the placebo
group (P = 0.001) [24]. The incidence of serious bleed-
ing in the PROWESS study was also higher in the
rhAPC group than in the placebo group (3.5% vs. 2.0%,
P = 0.06). In subgroup analyses, most of the benefit of
rhAPC treatment was seen in patients at increased risk
for death, including those with APACHE II scores of 25
or greater. A follow-up study, the Administration of
Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis
(ADDRESS) trial, evaluated the role of rhAPC in
patients with severe sepsis, associated with either single-
organ failure or an APACHE II score below 25 [10].
The study was stopped, after enrolling 2,640 patients,
Table 1 Definitions of organ failures
Organ Definition
Cardiovascular Blood pressure criteria are present for at least one hour despite adequate fluid resuscitation; arterial systolic BP <90 mmHg OR
Arterial systolic BP with 40 mmHg drop from baseline OR mean arterial pressure (MAP) <70 mmHg, and vasopressors are required to
maintain BP >90 mmHg systolic or MAP >70
Metabolic Serum lactate elevated >upper limits per lab
Renal Serum creatinine increased by more than 1 mg/dl from baseline after adequate fluid resuscitation OR serum creatinine > = 2 mg/dl,
in the absence of known baseline
a
Respiratory PaO2/FiO2 < = 300 OR requires PEEP >5 cm H2O
b
Hematologic Platelet count is half the highest value in the last three days OR Platelets <100,000/mm
3 OR PT/PTT >1.5 times control
c
a Does not apply to patients on chronic hemodialysis.
b Criteria apply to acute lung injury, not CHF or cardiogenic pulmonary edema.
c Not due to anticoagulant therapy.
Abbreviations: BP, blood pressure; mmHG, millimeters of mercury; mg, milligram; dl, deciliter; PaO2, partial pressure of oxygen in arterial blood; FiO2, fraction of
inspired oxygen; PEEP, positive end-expiratory pressure; PT, prothrombin time; PTT, partial thromboplastin time.
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Age in yrs, mean, SD
c 67.1(15.5) 62.9 (17.2) 64.2 (16.1) 0.53
Male
c 284 (50.4) 60 (55.6) 57 (52.8) 0.64
Body mass index, mean, SD
c 28.0 (8.6) 27.3 (7.8) 27.8 (7.5) 0.66
APACHE II, mean, SD
c 24.8 (8.3) 24.5 (8.4) 23.9 (8.3) 0.54
Comorbidities
Congestive heart failure
c 86 (15.3) 10 (9.2) 15 (13.9) 0.28
Diabetes
c 172 (30.5) 25 (23.2) 20 (18.5) 0.40
Hypertension
c 320 (56.9) 51(47.2) 53 (49.1) 0.76
Chronic pulmonary disease
c 266 (47.3) 42 (38.9) 40 (37.0) 0.77
Neurologic disease
c 8 (1.4) 1(0.9) 0 (0) 1.00
Chronic kidney disease
c 132 (23.5) 22 (20.4) 24 (22.2) 0.73
Cancer
c 121(21.5) 7 (6.5) 7 (6.5) 1.00
Chronic liver disease
c 36 (6.4) 10 (9.3) 8 (7.4) 0.62
Chronic pancreatitis
c 3 (0.5) 1(0.9) 1(0.9) 1.00
Organ failure
Kidney
c 161(28.6) 33 (30.6) 34 (31.5) 0.88
Respiratory
c 296 (52.6) 61 (56.5) 61 (56.5) 1.00
Hematologic
c 214 (38.0) 52 (48.1) 49 (45.4) 0.67
Metabolic/lactic acidosis
c 262 (46.5) 60 (55.6) 60 (55.6) 1.00
Number of organ failures
1 104 (18.5) 13 (12.0) 12 (11.1)
2 169 (30.0) 30 (27.8) 32 (29.6)
3 147 (26.1) 30 (27.8) 32 (29.6) 0.97
b
4 102 (18.1) 24 (22.2) 20 (18.5)
5 41 (7.3) 11 (10.2) 12 (11.1)
Inotrope
c 123 (21.9) 30 (27.8) 32 (29.6) 0.77
Steroid
c 219 (38.9) 50 (46.3) 46 (42.6) 0.59
Insulin drip
c 153 (27.2) 37 (34.3) 32 (29.7) 0.46
Statins
c 65 (11.6) 19 (17.6) 16 (14.8) 0.59
Chemical DVT prophylaxis
c 319 (56.7) 76 (70.4) 74 (68.5) 0.77
Sepsis source
Abdomen 86 (15.3) 12 (11.1) 20 (18.5)
Blood 34 (6.0) 9 (8.3) 3 (2.8)
Lung 251 (44.6) 54 (50.0) 42 (38.9) 0.08
b
Urinary Tract 101 (17.9) 20 (18.5) 22 (20.4)
Other/unknown 91 (16.2) 13 (12.0) 21 (19.4)
a The P-value for treated matched vs. untreated matched adjusted for matching by propensity.
b P-values, one for the number of organ failures, and one for sepsis source, because each test is being done as a chi-square test on a 2 × 5 crosstable.
c The 22 variables used in the propensity matching.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; DVT, deep vein thrombosis; P, P-value; SD, standard deviation; yrs, years.
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28-day rate of death from any cause was 18.5% in the
rhAPC group and 17% in the placebo group (P = 0.34).
The in-hospital mortality rate was 20.6% in the rhAPC
group and 20.5% in the placebo group (P =0 . 9 8 ) .S e r -
ious bleeding occurred in 2.4% of patients receiving
rhAPC and in 1.2% of patients receiving the placebo
(P = 0.02) during the drug-infusion period. No signifi-
cant difference was observed in the rate of intracranial
hemorrhage (0.3% with rhAPC and 0.2% with the
placebo) [10].
The efficacy of rhAPC in severe sepsis remains a mat-
ter of dispute. Some experts even criticized the Food
and Drug Administration’s decision to approve rhAPC
[24-26]. The main criticisms were aimed at intercurrent
changes made in the PROWESS protocol, among them
the exclusion of participants who were thought to be
likely to die within 28 days because of the severity of
the underlying disease and the introduction of new cell
l i n e sf o rg r o w i n gt h er h A P Cp r o t e i n .T h eu s eo fas u b -
group analysis of data from a major trial to identify
suitable candidates for treatment was also heavily criti-
cized. Mackenzie, Carlet and others suggested that a
general recommendation for the clinical use of rhAPC
was premature or not justified [27,28]. On the other
hand, Surviving Sepsis Guidelines suggested the use of
rhAPC for severe septic patients who have multiorgan
failure or a high risk of death [21]. As a result, two large
multicenter, randomized, double-blind trials investigat-
ing the use of rhAPC in septic shock are currently
underway [17,18].
The patients in our trial had mortality rates higher
than those observed in the PROWESS trial, possibly
b e c a u s ew eo n l ys t u d i e ds e p t i cs h o c kp a t i e n t st h a t
might be sicker than the patient population in PRO-
WESS. In our study, we had fewer patients with single
organ failure, a similar number of patients with two or
three organ failures, but more patients with four or five
organ failures than PROWESS. In our study, the more
organ failures, the higher was the mortality in both
groups. Across all organ failure subgroups (one, two,
three, four, or five organ failure subgroups), in-hospital
mortality was persistently higher in the group that did
not receive rhAPC than the group that received rhAPC
(data not shown). The higher relative risk reduction in
mortality in our study (33.9% vs 13% in PROWESS) is
likely due to the fact that rhAPC is most beneficial in
the sickest septic shock patients, with multiple organ
failures. The bleeding rate in our study was smaller than
that observed in PROWESS, but similar to that observed
in other major clinical trials [23].
I no u rs t u d y ,t h e r ew a sn od i f f e r e n c eb e t w e e nt h e
matched treated and matched untreated groups in days
on vasopressors, days on mechanical ventilation, length
of ICU stay in days, and length of hospital stay in days
(Table 3). These findings are not surprising and are
similar to those found in PROWESS [9]. This adds to
the evidence that survivors of treated versus untreated
groups look fairly similar, but more patients survived in
the treated group. This also suggests that rhAPC
improves hospital survival without the consumption of
additional resources.
Our study is limited in that it is a retrospective analy-
sis and that the number of patients is relatively small.
However, this propensity analysis provides an estimate
of the benefit of rhAPC in a natural hospital setting.













Length of stay, median days, (IQR)
b 22 (12, 39) 19.5 (11, 33) 27 (12, 45) 0.11
Hospital mortality 266 (47.2) 38 (35.2) 57 (53.8) 0.005
Intensive care unit outcomes
Mortality 226 (40.1) 36 (33.3) 47 (43.5) 0.09
Length of stay, median days, (IQR) 9.3 (4.0, 21.3) 11 (6, 22) 11.3 (4.5, 28) 0.90
Days on ventilator, median, (IQR) 8.8 (3.7, 22.6) 9 (6, 22) 8.7 (4.3, 24) 0.80
Days on vasopressors, median, (IQR) 2 (1, 3) 2 (1, 4) 2 (1, 3) 0.90
Complications
Gastrointestinal bleeding 9 (1.6) 3 (2.8) 0 (0.0) 1.00
Intracranial bleeding 1 (0.2) 0 (0) 0 (0) 1.00
Minor transfusion 216 (38.4) 38 (35.2) 45 (41.7) 0.27
Major transfusion 45 (8.5) 4 (3.7) 10 (9.3) 0.09
Any transfusion(minor and/or major) 243 (43.2) 41 (38.0) 50 (46.3) 0.16
a The P-value for treated matched vs. untreated matched adjusted for matching by propensity.
b IQR, interquartile range.
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randomized controlled trial (RCT), where conditions are
more controlled. An RCT tells us that there is a causal
effect of a certain size. A propensity analysis of retrospec-
tive data tells us what size effect we can expect under
normal hospital conditions. Also, fewer patients (110)
received rhAPC than those who did not (453). This could
be explained by the possibility that treatment was prefer-
entially directed toward patients thought to have a higher
likelihood of meaningful survival, a lower risk of bleeding,
or contraindication to rhAPC by the managing intensi-
vist. However, it is not explained by differences in the
types of patients receiving it versus not since we used all
possible recorded pre-treatment variables. In addition,
the 108 untreated patients are also candidates for rhAPC
therapy in the sense that they have propensities to receive
rhAPC that match the propensities of those 108 patients
actually receiving rhAPC. There was also no evidence of
a difference in any of the bleeding variables between the
two groups (Table 3). Usage of rhAPC also depended
upon whether the intensivist caring for the patient was
critical or supportive of rhAPC. However, usage of
rhAPC has remained constant over the study period,
seen graphically and by non-significant hypothesis tests
(t-test, Wilcoxon test and logistic regression all have
P- v a l u e sn e a r0 . 5 ) .O u rp r i mary outcome measure was
in-hospital mortality; we did not have access to longer-
term outcomes, and, thus, our survival analyses assumed
patients who were discharged alive from the hospital
were in fact alive at Day 28. However, this study is made
stronger by the propensity-matched analysis. Our pri-
mary outcome was in-hospital mortality, and rhAPC
began to show its effect in the ICU (Table 3). ICU mor-
tality comes close to statistical significance with P = 0.09;
however, if we make the test one-sided in the hypothe-
sized direction, the P-value becomes 0.045. In-hospital
mortality shows fuller statistical significance (which of
course includes ICU mortality). A recent similar study
conducted by Lindenauer et al. showed similar results
[29]. In a propensity-matched sample in which all covari-
ates achieved balance, receipt of rhAPC was associated
with reduced hospital mortality (40.7% vs. 46.6%; risk
ratio, 0.87; 95% confidence interval, 0.80 to 0.95). Four
rhAPC-treated patients (0.25%) had hemorrhagic stroke,
107 (6.8%) had gastrointestinal bleeding, and five (0.3%)
required major transfusion [29]. An important limitation
of the study by Lindenauer et al.i st h a ta l lt h ed a t ao n
their patients were based on billing records, and not
direct clinical measurements.
Conclusions
Patients with septic shock who were treated with rhAPC
had a reduced in-hospital mortality compared with
patients with septic shock with similar acuity who were
not treated with rhAPC. In addition, time on mechanical
ventilation, time on vasopressors, length of ICU stay and
bleeding complications did not differ between the
groups. Pending results from large multicenter studies
evaluating rhAPC in septic shock patients, our analysis
adds to the evidence that early initiation of rhAPC may
improve survival of patients with septic shock who are
at low risk of bleeding.
Key messages
￿ The efficacy of recombinant human activated pro-
tein C (rhAPC) in sepsis remains a matter of
dispute.
￿ Pending results from two large multicenter, rando-
mized, double-blind trials, we examined the association
between treatment with rhAPC and outcomes among
patients with septic shock in routine clinical practice in
a large university-affiliated Intensive Care Unit.
￿ We performed a propensity-matched analysis,
which equalizes the probability of receiving rhAPC,
mimicking a randomized comparison.
￿ Patients with septic shock who were treated with
rhAPC had reduced in-hospital mortality compared
with patients with septic shock with similar acuity
who were not treated with rhAPC, with no differ-
ence in complications.
￿ Our analysis provides an estimate of the benefit of
rhAPC in septic shock patients in a natural hospital
setting.
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